Jim has more than 25 years’ of international experience in both private and government sectors encompassing sales, marketing, business development and the UK Department of International Trade

Ex-GW program leader for the EU & ROW commercialization of Epidyolex®, and re-commercialisation of Sativex® in the UK

Led GW’s Brexit readiness project ensuring regulatory, supply chain, finance, and legal preparedness irrespective of the final political solution

Ex-Jazz Pharma commercial program leader for the acquisition of GW and the divestment of Sunosi® to Axsome Therapeutics